Although the observed prognostic impact of KRAS+TP53 co-mutations in stage I–II NSCLC was statistically significant (HR = 0.15, p = 0.01), we acknowledge that this analysis was based on a limited number of patients. Here, KRAS is linked to non-small cell lung carcinoma.